Based on the Cyclacel Pharmaceuticals Inc stock forecast from 0 analysts, the average analyst target price for Cyclacel Pharmaceuticals Inc is not available over the next 12 months. Cyclacel Pharmaceuticals Inc’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of Cyclacel Pharmaceuticals Inc is Bearish, which is based on 2 positive signals and 6 negative signals. At the last closing, Cyclacel Pharmaceuticals Inc’s stock price was USD 0.24. Cyclacel Pharmaceuticals Inc’s stock price has changed by +11.68% over the past week, -21.28% over the past month and -86.42% over the last year.
No recent analyst target price found for Cyclacel Pharmaceuticals Inc
No recent average analyst rating found for Cyclacel Pharmaceuticals Inc
Company Overview Cyclacel Pharmaceuticals Inc
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies. It has a clinical collaboration agreement with the University of Texas MD Anderson Cancer Center to clinically evaluate the safety and efficacy of three cyclacel medicines in patients with hematological malignancies, including chronic lymphocytic leukemias, acute myeloid leukemias, myelodysplastic syndromes, and other advanced leukemias. The company was founded in 1996 and is headquartered in Berkeley Heights, New Jersey. Read Less
Cyclacel Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dep...Read More
Frequently Asked Questions About Cyclacel Pharmaceuticals Inc (CYCC) Stock
Stock Target Advisor's fundamental analysis for Cyclacel Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on CYCC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CYCC's stock to indicate what its average analyst target is.
CYCC stock's Price/Earning ratio is 0.27.
Our analysis grades CYCC stock's Price / Earning ratio at B-. This means that CYCC stock's Price/Earning ratio is above 20% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CYCC may be undervalued for its sector.
The last closing price of CYCC's stock was USD 0.24.
The most recent market capitalization for CYCC is USD 0.07B.
Unfortunately we do not have enough analyst data on CYCC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cyclacel Pharmaceuticals Inc's stock.
As per our most recent records Cyclacel Pharmaceuticals Inc has 0 Employees.
Cyclacel Pharmaceuticals Inc's registered address is 200 Connell Drive, Berkeley Heights, NJ, United States, 07922.
You can get more information about it from Cyclacel Pharmaceuticals Inc's website at https://www.cyclacel.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Underpriced compared to earnings
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
What not to like
Overpriced compared to book value
The stock is trading high compared to its peers median on a price to book value basis.
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Cyclacel Pharmaceuticals Inc (CYCC) Stock
Stock Target Advisor's fundamental analysis for Cyclacel Pharmaceuticals Inc's stock is Bearish.
Unfortunately we do not have enough data on CYCC's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on CYCC's stock to indicate what its average analyst target is.
CYCC stock's Price/Earning ratio is 0.27.
Our analysis grades CYCC stock's Price / Earning ratio at B-. This means that CYCC stock's Price/Earning ratio is above 20% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this CYCC may be undervalued for its sector.
The last closing price of CYCC's stock was USD 0.24.
The most recent market capitalization for CYCC is USD 0.07B.
Unfortunately we do not have enough analyst data on CYCC's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains Cyclacel Pharmaceuticals Inc's stock.
As per our most recent records Cyclacel Pharmaceuticals Inc has 0 Employees.
Cyclacel Pharmaceuticals Inc's registered address is 200 Connell Drive, Berkeley Heights, NJ, United States, 07922.
You can get more information about it from Cyclacel Pharmaceuticals Inc's website at https://www.cyclacel.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for CYCC !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
